No More Pandemics: Toward a World Free from Infectious Diseases

Front Cover
Cambridge Scholars Publishing, Apr 16, 2024 - Medical - 178 pages
This book proposes a concrete path to bring an end to pandemics and achieve a world without infectious diseases, suggesting an escape from the long history of infectious diseases that have brought misery and confusion to humanity. The book presents an Mikawa-Kase-AQIP model to illuminate the generation of infection units originating from the lungs, where viral proliferation occurs. It further elucidates the theoretical distribution of viruses entrapped within aerosol particles.

It is entirely possible to avoid infection using today’s science and technology, if we all understand, share, and implement an air ventilation approach which will stop viruses from entering the body. The challenge to eradicate future pandemics must be confronted now. The aim in this book is to present the answer.

 

Contents

1
1
2
15
3
40
4
45
5
62
Summary and Conclusion
83
Florence Nightingale
90
References and Notes
92
Appendices
101
Acknowledgements
142
Abbreviations and Glossary
144
Index
159
Copyright

Other editions - View all

Common terms and phrases

About the author (2024)

Hiroshi Kase, PhD, joined Kyowa Hakko Kogyo Co., Ltd. (Japan) in 1966, and served as researcher, as Director of the Pharmaceutical Research Institute and as Global Project Leader. As a representative accomplishment, he was involved in the discovery and development of adenosine A2A antagonist KW-6002 (istradefylline) for a new Parkinson’s Disease drug with a novel action mechanism, leading to success in its launch in Japan and the United States. He is the author and editor of “Adenosine Receptor and Parkinson’s Disease” (2000).

Yoshikazu G. Mikawa, MD, PhD joined Dr Sydney Brenner’s Molecular Genetics Unit in Cambridge, UK, in 1989 and collaborated in the USA until 2005. His work propelled DNA technologies, particularly in the next-generation sequencing. He developed a bacteriophage lambda peptide display system and genetically modified bacteria for ligand-receptor binding analysis. He was Principal Scientific Officer at Population Genetics Technologies Ltd, UK (2005-2013). He co-founded Nemesis Bioscience Ltd (UK) in 2014, focusing on cutting-edge technologies addressing antimicrobial resistance.

Bibliographic information